Dianthus Therapeutics, INC /DE/ 8-K filings

Dianthus Therapeutics announced Q2 2026 financial results, highlighting progress in clinical trials for claseprubart and DNTH212, and maintaining a substantial cash reserve.

Dianthus Therapeutics announced a 75% responder rate in the interim analysis of its Phase 3 CAPTIVATE trial for claseprubart in CIDP.

Dianthus Therapeutics stockholders re-elected three Class II directors and ratified the appointment of Deloitte & Touche as auditor.

Dianthus Therapeutics announced Q1 2026 financial results, highlighting progress in clinical trials for claseprubart and DNTH212, and a strengthened balance sheet.

Dianthus Therapeutics, Inc. announced FDA agreement to modify screening criteria and risk classification for its claseprubart clinical trials, alongside an updated corporate presentation highlighting strong financial position and pipeline progress.

Dianthus Therapeutics successfully completed a public offering of common stock and pre-funded warrants, raising approximately $673.5 million in net proceeds.

Dianthus Therapeutics reports a robust cash position of $514 million and positive Phase 2 results for its lead candidate, claseprubart, in generalized myasthenia gravis.

Dianthus Therapeutics announced its third-quarter 2025 financial results and provided updates on its clinical pipeline, including accelerated timelines for its CAPTIVATE trial.

Dianthus Therapeutics presents positive Phase 2 gMG results for Claseprubart and outlines a robust pipeline with a cash runway into 2028.

Dianthus Therapeutics secures exclusive global rights outside Greater China for DNTH212, a bifunctional autoimmune therapy, bolstering its pipeline and extending cash runway into 2028.

Dianthus Therapeutics, Inc. has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $270.0 million in net proceeds.

Dianthus Therapeutics announced positive top-line data from its Phase 2 MaGic trial for claseprubart (DNTH103) in generalized Myasthenia Gravis, demonstrating significant efficacy and a favorable safety profile.

Dianthus Therapeutics reported increased Q2 2025 net loss while highlighting significant progress in its claseprubart clinical pipeline and maintaining a strong cash runway into 2H27.

Dianthus Therapeutics reports the resignation of a director, appointment of a new director, and the results of its annual stockholder meeting.

Dianthus Therapeutics announces Q1 2025 financial results, highlighting the completion of enrollment in the Phase 2 MaGic trial for DNTH103 in generalized Myasthenia Gravis (gMG) and providing a cash runway into 2H27.

Dianthus Therapeutics announced its Q4 and full year 2024 financial results, highlighting the progress of its clinical trials for DNTH103 and a cash runway into 2H27.

Dianthus Therapeutics reports the resignation of Tomas Kiselak from the Board of Directors and the appointment of Sujay Kango as a new Class II director and Compensation Committee member, effective March 4, 2025.

Dianthus Therapeutics has released an updated corporate presentation detailing the progress of its lead drug candidate, DNTH103, and its clinical development plans.

Dianthus Therapeutics reported its Q3 2024 financial results, highlighted by a strong cash position and progress in clinical trials for its lead drug candidate, DNTH103.

Dianthus Therapeutics has appointed Steven Romano, M.D. to its Board of Directors and Science and Technology Committee, effective immediately.

Dianthus Therapeutics announced its second quarter 2024 financial results, highlighting progress in its clinical programs and a strong cash position.

Dianthus Therapeutics is progressing its lead drug candidate, DNTH103, a novel monoclonal antibody, into multiple Phase 2 trials after demonstrating promising Phase 1 results.

Dianthus Therapeutics held its annual meeting where stockholders approved the amended stock option and incentive plan, elected two Class III directors, and ratified the appointment of Deloitte & Touche as the company's independent auditor.

Dianthus Therapeutics announced its first quarter 2024 financial results, highlighted by a $377 million cash position and progress in clinical trials for its lead drug candidate, DNTH103.

Dianthus Therapeutics announced its Q4 and full-year 2023 financial results, highlighted by the initiation of a Phase 2 trial for DNTH103 and a successful PIPE financing.

Dianthus Therapeutics has successfully raised approximately $230 million through a private placement to fund research and development of its antibody complement therapeutics.